Aclidinium bromide vs tiotropium: Non‐fatal serious adverse events
It is very uncertain whether aclidinium bromide changes non‐fatal serious adverse events compared with tiotropium (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Aclidinium bromide vs tiotropium Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease It is very uncertain whether aclidinium bromide changes non‐fatal serious adverse events compared with tiotropium (very low certainty). Aclidinium bromide for stable chronic obstructive pulmonary disease (2014) · Cochrane Headline outcomes only | OR 0.67 [0.17, 2.65] | 2 studies · 729 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Aclidinium bromide for stable chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.